Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs when a mother’s immune system makes antibodies that attack her baby’s platelets. This can lead to very low platelet counts and increase the risk of bleeding, including dangerous brain bleeds before or shortly after birth.
Detecting FNAIT risk early is essential to prevent complications, but relying only on the mother’s blood samples may not provide the full picture.
Why maternal blood testing isn’t always enough
Maternal blood testing for FNAIT is fairly straightforward. A sample from the mother is taken and analyzed to determine whether she carries antibodies that could harm the baby’s platelets. If present, these antibodies suggest a potential incompatibility between maternal and fetal platelet types. However, several factors complicate this seemingly simple test.
One challenge is that not all platelet antibodies are detectable early in pregnancy. In many cases, antibodies against specific platelet antigens develop only after a woman has been exposed to fetal platelets during a prior pregnancy or delivery. For first-time mothers, or those in early stages of subsequent pregnancies, antibody levels may be too low to register on standard tests. This means a pregnancy could be at risk even when the maternal blood sample appears negative.
Limitations of current tests
Another complication lies in the variability of laboratory techniques. Detecting platelet-specific antibodies requires highly specialized assays, and not all labs use the same methods or have equal sensitivity.
Certain antibodies can also be particularly difficult to detect, which means a risk may be missed.
Learn more about FNAIT prognosis
Antibody levels don’t always predict outcomes
Another challenge is that antibody levels in the mother’s blood don’t always predict how sick the baby might get. Some mothers have high antibody levels but deliver babies who never develop dangerously low platelets. Others have very low antibody levels but still face serious complications.
This disconnect can make it hard for doctors to use maternal blood results alone to determine how severe FNAIT may be.
The role of genetics
Genetics also plays a role. FNAIT most commonly involves incompatibility at the HPA-1a platelet antigen, but other antigens can also trigger the condition.
If a mother is screened only for the most common incompatibility, rarer but still dangerous mismatches may be overlooked. Without comprehensive genetic and serologic testing, maternal blood samples can miss these less common scenarios.
What families should know
It’s important for families to understand that a negative maternal blood test doesn’t always mean the pregnancy is risk-free. While these tests are a helpful starting point, they don’t tell the whole story.
Researchers are working on more reliable ways to identify and manage FNAIT to give parents and doctors more confidence in protecting babies at risk. Combining antibody screening with genetic testing of both parents may also give a clearer picture.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
